{"classes":[{"categories":[{"measurements":[{"comment":"KM estimate at Year 5 was NA due to insufficient patients and/or follow-up. 95% CIs were NA due to insufficient patients and/or follow-up.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of 95% CI was NA due to insufficient patients and/or follow-up.","groupId":"OG001","lowerLimit":"81.5","upperLimit":"NA","value":"81.5"},{"comment":"KM estimate at Year 4 was NA due to insufficient patients and/or follow-up. Upper limit of 95% CI was NA due to insufficient patients and/or follow-up.","groupId":"OG002","lowerLimit":"0.9","upperLimit":"NA","value":"NA"},{"comment":"KM estimate at Year 4 was NA due to insufficient patients and/or follow-up. Upper limit of 95% CI was NA due to insufficient patients and/or follow-up.","groupId":"OG003","lowerLimit":"11.1","upperLimit":"NA","value":"NA"},{"comment":"KM estimate at Year 4 was NA due to insufficient patients and/or follow-up. Upper limit of 95% CI was NA due to insufficient patients and/or follow-up.","groupId":"OG004","lowerLimit":"68.5","upperLimit":"NA","value":"NA"},{"comment":"KM estimate at Year 4 was NA due to insufficient patients and/or follow-up. Upper limit of 95% CI was NA due to insufficient patients and/or follow-up.","groupId":"OG005","lowerLimit":"14.1","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of 95% CI was NA due to insufficient patients and/or follow-up.","groupId":"OG006","lowerLimit":"11.8","upperLimit":"NA","value":"20.4"},{"comment":"Upper limit of 95% CI was NA due to insufficient patients and/or follow-up.","groupId":"OG007","lowerLimit":"14.6","upperLimit":"NA","value":"35.4"},{"groupId":"OG008","lowerLimit":"4.0","upperLimit":"10.1","value":"7.9"},{"groupId":"OG009","lowerLimit":"0.9","upperLimit":"5.5","value":"1.8"},{"groupId":"OG010","lowerLimit":"0.7","upperLimit":"3.8","value":"1.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"50"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"49"},{"groupId":"OG007","value":"30"},{"groupId":"OG008","value":"36"},{"groupId":"OG009","value":"28"},{"groupId":"OG010","value":"24"}],"units":"Participants"}],"description":"PFS was based on Kaplan-Meier method. Disease progression was determined by the investigator as the reason for treatment discontinuation and death was due to any cause within 30 days of last dose. Duration in months = (date of PD/death or last valid cytogenetic/hematologic assessment if censored - first dose date)/30.4.\n\nNA = not estimable. One year = 12 months","dispersionType":"95% Confidence Interval","groups":[{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-R CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG000","title":"Bosutinib 500 mg, CP2L-CML IM-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG001","title":"Bosutinib 500 mg, CP2L-CML IM-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I, D and NI R/I or IM R/I and NI-I CML.","id":"OG002","title":"Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-R CML.","id":"OG003","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-I CML.","id":"OG004","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and NI-R CML.","id":"OG005","title":"Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with AP IM R/I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG006","title":"Bosutinib 500 mg, AP-CML IM R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with AP Multi-TKI: IM, D and/or NI R/I CML.","id":"OG007","title":"Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with BP IM R/I CML ; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG008","title":"Bosutinib 500 mg, BP-CML IM R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with BP Multi-TKI: IM, D and/or NI R/I CML.","id":"OG009","title":"Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with Ph+ ALL","id":"OG010","title":"Bosutinib 500 mg, Ph+ ALL (Part 2)"}],"paramType":"MEDIAN","populationDescription":"All-treated population included all enrolled participants who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"Years 1, 2, 3, 4, and 5 (CP2L only)","title":"Progression Free Survival (PFS) - Part 2","type":"SECONDARY","unitOfMeasure":"Months"}